TransCode Therapeutics, Inc.
RNAZ
$1.77
-$0.13-6.61%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.92M | 7.04M | 5.77M | 5.46M | 5.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.36M | 23.35M | 19.19M | 17.05M | 14.65M |
| Operating Income | -25.36M | -23.35M | -19.19M | -17.05M | -14.65M |
| Income Before Tax | -42.38M | -39.90M | -34.44M | -27.13M | -24.60M |
| Income Tax Expenses | 457.70K | 457.40K | 226.10K | -- | -- |
| Earnings from Continuing Operations | -42.83 | -40.36 | -34.66 | -27.13 | -24.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.83M | -40.36M | -34.66M | -27.13M | -24.60M |
| EBIT | -25.36M | -23.35M | -19.19M | -17.05M | -14.65M |
| EBITDA | -25.26M | -23.26M | -19.12M | -17.00M | -14.60M |
| EPS Basic | -50.76 | -48.72 | -97.60 | -362.35 | -502.59 |
| Normalized Basic EPS | -16.95 | -15.90 | -54.81 | -225.58 | -313.23 |
| EPS Diluted | -50.76 | -48.72 | -97.60 | -362.35 | -502.59 |
| Normalized Diluted EPS | -16.95 | -15.90 | -54.81 | -225.58 | -313.23 |
| Average Basic Shares Outstanding | 3.62M | 3.50M | 2.75M | 1.86M | 1.04M |
| Average Diluted Shares Outstanding | 3.62M | 3.50M | 2.75M | 1.86M | 1.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |